{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Allogeneic+Hematopoietic+Stem+Cell+Transplant+Recipient",
    "query": {
      "condition": "Allogeneic Hematopoietic Stem Cell Transplant Recipient"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 41,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Allogeneic+Hematopoietic+Stem+Cell+Transplant+Recipient&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:41:46.183Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03272633",
      "title": "Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia in Remission",
        "Hematopoietic Cell Transplantation Recipient",
        "JAK2 Gene Mutation",
        "Loss of Chromosome 17p",
        "Mantle Cell Lymphoma",
        "Minimal Residual Disease",
        "Myelodysplastic Syndrome",
        "Non-Hodgkin Lymphoma",
        "Plasma Cell Myeloma",
        "RAS Family Gene Mutation",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Hematologic Malignancy",
        "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Therapy-Related Acute Myeloid Leukemia",
        "Therapy-Related Myelodysplastic Syndrome",
        "TP53 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Irradiated Allogeneic Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-10-26",
      "completion_date": "2022-09-22",
      "has_results": true,
      "last_update_posted_date": "2023-06-26",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03272633"
    },
    {
      "nct_id": "NCT03851081",
      "title": "Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation Recipient",
        "Blasts 5 Percent or More of Bone Marrow Nucleated Cells",
        "Blasts 5 Percent or More of Peripheral Blood White Cells",
        "CD22 Positive",
        "Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells",
        "Lymphoblasts 20 Percent or More of Peripheral Blood White Cells",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Vincristine Sulfate Liposome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-01-21",
      "completion_date": "2024-01-21",
      "has_results": false,
      "last_update_posted_date": "2022-01-28",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03851081"
    },
    {
      "nct_id": "NCT04127721",
      "title": "Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Stem Cell Transplant Recipient",
        "Hematologic and Lymphocytic Disorder",
        "Hematopoietic and Lymphoid Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-09-22",
      "completion_date": "2020-09-22",
      "has_results": false,
      "last_update_posted_date": "2020-10-29",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04127721"
    },
    {
      "nct_id": "NCT00006184",
      "title": "Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Myeloma Immunoglobulin Idiotype Vaccine",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "GMCSF (granulocyte macrophage colony stimulating factor)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GCSF (granulocyte colony stimulating factor)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2001-02-08",
      "completion_date": "2008-01-12",
      "has_results": true,
      "last_update_posted_date": "2017-10-20",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006184"
    },
    {
      "nct_id": "NCT03494569",
      "title": "Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia in Remission",
        "Hematopoietic Cell Transplantation Recipient",
        "Minimal Residual Disease",
        "Myelodysplastic Syndrome",
        "Secondary Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Total Marrow Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2018-07-06",
      "completion_date": "2026-06-11",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03494569"
    },
    {
      "nct_id": "NCT00423774",
      "title": "Education Program to Manage Emotional Stress of Stem Cell Transplant Recipients and Their Caregivers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Family Caregivers",
        "Bone Marrow Transplantation"
      ],
      "interventions": [
        {
          "name": "Problem-Solving Education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-01-11",
      "completion_date": "2008-12-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423774"
    },
    {
      "nct_id": "NCT01822509",
      "title": "Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplant Recipient",
        "Myeloproliferative Neoplasm",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Recurrent Hematologic Malignancy",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Myelodysplastic Syndrome",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2013-05-16",
      "completion_date": "2021-06-10",
      "has_results": false,
      "last_update_posted_date": "2021-06-24",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 13,
      "location_summary": "Duarte, California • La Jolla, California • South Pasadena, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01822509"
    },
    {
      "nct_id": "NCT02210065",
      "title": "Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2015-03-03",
      "completion_date": "2019-05-13",
      "has_results": true,
      "last_update_posted_date": "2020-03-17",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02210065"
    },
    {
      "nct_id": "NCT03560752",
      "title": "CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Accelerated Phase CML, BCR-ABL1 Positive",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia in Remission",
        "Chronic Lymphocytic Leukemia",
        "Chronic Phase CML, BCR-ABL1 Positive",
        "Cytomegalovirus Positive",
        "Donor",
        "Hematopoietic Cell Transplant Recipient",
        "Hodgkin Lymphoma",
        "Myelodysplastic Syndrome",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Non-Hodgkin Lymphoma",
        "Myelofibrosis",
        "Hematopoietic and Lymphoid Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 34,
      "start_date": "2018-08-20",
      "completion_date": "2026-07-29",
      "has_results": true,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03560752"
    },
    {
      "nct_id": "NCT03665675",
      "title": "Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation Recipient",
        "Cytomegalovirus",
        "Donor",
        "Solid Organ Transplantation Recipient",
        "Adenovirus"
      ],
      "interventions": [
        {
          "name": "Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sumithira Vasu",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "1 Year to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-11-07",
      "completion_date": "2026-12-20",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-21T23:41:46.183Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03665675"
    }
  ]
}